Bystander injury of host lymphoid tissue during murine graft-versus-host disease is mediated by nitric oxide

Transplantation

Volumn 61, Issue 4, 1996, Pages 610-618

  Hoffman, Rosemary A ^a   Langrehr, Jan M ^b   Berry, Luann M ^a   White, David A ^a   Schattenfroh, Natascha C ^a   Mccarthy, Susan A ^a   Simmons, Richard L ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRAFT VERSUS HOST REACTION; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SPLEEN CELL; TISSUE INJURY;

ANIMALS; BODY WEIGHT; CELL TRANSPLANTATION; CYTOTOXICITY, IMMUNOLOGIC; ENZYME INHIBITORS; FEMALE; GRAFT VS HOST DISEASE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GUANIDINES; LYMPHOCYTE SUBSETS; LYMPHOCYTES; LYMPHOID TISSUE; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NITRATES; NITRIC OXIDE; NITRITES; SPLEEN;

EID: 0029923375     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199602270-00016     Document Type: Article

References (39)

1. 1 mice injected with parental lymphocytes. J Immunol 1991; 146: 2108.
2. Xenocostas A, Osmond DG, Lapp WS. The effect of the graft-versus-host reaction on B lymphocyte production in bone marrow of mice: depressed genesis of early progenitors prior to M heavy chain expression. Transplantation 1991; 51: 1089.
3. Hakim FT, Shearer GM. Immunologic and hematopoietic deficiencies of graft-vs.-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson X, eds. Graft-vs.-host disease: immunology, pathophysiology, and treatment. New York: Dekker, 1990: 133.
4. Hakim FT, Payne S, Shearer GM. Recovery of T cell populations after acute graft-vs.-host reaction. J Immunol 1994; 152: 58.
5. Hoffman RA, Langrehr JM, Billiar TR, Curran RD, Simmons RL. Alloantigen-induced activation of rat splenocytes is regulated by the oxidative metabolism of L-arginine. J Immunol 1990; 145: 2220.
6. Albina JE, Henry WL Jr. Suppression of lymphocyte proliferation through the nitric oxide synthesizing pathway. J Surg Res 1991; 50: 403.
7. Mills CD. Molecular basis of "suppressor" macrophages: arginine metabolism via the nitric oxide synthetase pathway. J Immunol 1991; 146: 2719.
8. Langrehr JM, Dull KE, Ochoa JB, et al. Evidence that nitric oxide production by in vivo allosensitized cells inhibits the development of allospecific CTL. Transplantation 1992; 53: 632.
9. Langrehr JM, Murase N, Markus PM, et al. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. J Clin Invest 1992; 90: 679.
10. Langrehr JM, Müller AR, Bergonia HA, et al. Detection of nitric oxide by EPR spectroscopy during rejection and graft-versus-host disease following small-bowel transplantation in the rat. Surgery 1992; 112: 395.
11. Hoffman RA, Langrehr JM, Wren SM, et al. Characterization of the immunosuppressive effects of nitric oxide during graft-versus-host disease. J Immunol 1993; 151: 1508.
12. 15N] nitrate in biological fluids. Anal Biochem 1982; 126: 131.
13. Lowry OH, Rosenbrough NJ, Fan AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265.
14. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 6: 3051.
15. Ferrara JLM, Deeg JH. Graft-versus-host disease. N Engl J Med 1991; 324: 667.
16. Piguet P-F, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/ cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987; 166: 1280.
17. + T cell clones specific for non-H-2 antigens. J Immunol 1990; 145: 2123.
18. Garside P, Hutton AK, Severn A, Liew FY, Mowat AM. Nitric oxide mediates intestinal pathology in graft-vs.-host disease. Eur J Immunol 1992; 22: 2141.
19. Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL, Tilton RG. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest 1994; 93: 2684.
20. McCartney-Francis N, Allen JB, Mizel DE, et al. Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 1993; 178: 749.
21. Stefanovic-Racic M, Meyers K, Meschter C, Coffey JW, Hoffman RA, Evans CH. N-monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. Arthritis Rheum 1994; 37: 1062.
22. Corbett JA, Mikhael A, Shimizu J, et al. Nitric oxide production in islets from nonobese diabetic mice: aminoguanidine-sensitive and -resistant stages in the immunological diabetic process. Proc Natl Acad Sci USA 1993; 90: 8992.
23. G-monomethyl-L-arginme. J Exp Med 1994; 179: 651.
24. Worrall NK, Lazenby WD, Misko TP, et al. Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase. J Exp Med 1995; 181: 63.
25. W-monomethyl-L-arginine inhibits nitric oxide production in murine cardiac allografts but does not affect graft rejection. Biochim Biophys Acta 1994; 1226: 225.
26. Hibbs JB Jr, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988; 157: 87.
27. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620.
28. Albina JE, Cui S, Mateo RB, Reichner JS. Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J Immunol 1993; 150: 5080.
29. Lepoivre M, Chenais B, Yapo A, Lemaire G, Thelander L, Tenu JP. Alteration of ribonucleotide reductase activity following induction of the nitrite-generating pathway in adenocarcinoma cells. J Biol Chem 1990; 265: 14,143.
30. Klimpel GR, Annable CR, Cleveland MG, Jerrells TR, Patterson JC. Immunosuppression and lymphoid hypoplasia associated with chronic graft versus host disease is dependent upon IFN-g production. J Immunol 1990; 144: 84.
31. Durie FH, Aruffo A, Ledbetter J, et al. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest 1994; 94: 1333.
32. Corbett JA, Tilton RG, Chang K, et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992; 41: 552.
33. Misko TP, Moore WM, Kasten TP, et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993; 233: 119.
34. G-nitro-L-arginine, and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem Biophys Res Commun 1994; 199: 147.
35. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629.
36. Huijberts MSP, Wolffenbuttel BHR, Struijker Boudier HAJ, et al. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 1993; 92: 1407.
37. Bucala R, Makita Z, Vega G, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994; 91: 9441.
38. Picard S, Parthasarathy S, Fruebis J, Witztum JL. Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 1992; 89: 6876.
39. Lindell SE, Nilsson K, Roos B-E, Westling H. The effect of enzyme inhibitors on histamine catabolism in man. Br J Pharmacol 1960; 15: 351.